DREAM Antibody (A-9): sc-166916

DREAM Antibody (A-9) is a mouse monoclonal IgG2b kappa light chain antibody that detects DREAM protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-DREAM antibody (A-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. DREAM protein, known as DRE-antagonist modulator, functions as a calcium-regulated transcriptional repressor that specifically binds to downstream regulatory elements (DRE), which are crucial for silencing basal transcription. This regulatory sequence is located in the promoter region of the gene encoding human prodynorphin, an opioid peptide that plays a significant role in memory acquisition and pain modulation. DREAM′s ability to form functional homotetramers is essential for DRE interaction, and this binding is highly sensitive to calcium levels; an increase in calcium concentration inhibits DREAM′s binding capacity, thereby blocking repressive activity. DREAM transcripts are predominantly found in the brain, thymus, and thyroid gland, where DREAM is expressed as a nuclear protein. DREAM has been shown to inhibit the transcription of other genes containing DRE-like motifs, including the gene for the AP-1 transcription factor c-Fos, indicating a broader influence on various cellular genes and pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DREAM Antibody (A-9) References:

1. Cell signalling. DREAM on without calcium.  |  Mandel, G. and Goodman, RH. 1999. Nature. 398: 29-30. PMID: 10078526
2. DREAM is a Ca2+-regulated transcriptional repressor.  |  Carrión, AM., et al. 1999. Nature. 398: 80-4. PMID: 10078534
3. Ca(2+)-dependent prodynorphin transcriptional derepression in neuroblastoma cells is exerted through DREAM protein activity in a kinase-independent manner.  |  Campos, D., et al. 2003. Mol Cell Neurosci. 22: 135-45. PMID: 12676525
4. Transcriptional repressor DREAM interacts with thyroid transcription factor-1 and regulates thyroglobulin gene expression.  |  Rivas, M., et al. 2004. J Biol Chem. 279: 33114-22. PMID: 15181011
5. Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression.  |  Savignac, M., et al. 2005. EMBO J. 24: 3555-64. PMID: 16177826
6. DREAM (downstream regulatory element antagonist modulator) contributes to synaptic depression and contextual fear memory.  |  Wu, LJ., et al. 2010. Mol Brain. 3: 3. PMID: 20205763
7. Role of ion flux in the control of c-fos expression.  |  Morgan, JI. and Curran, T. Nature. 322: 552-5. PMID: 2426600
8. Hydrogen-Deuterium Exchange Mass Spectrometry Reveals Calcium Binding Properties and Allosteric Regulation of Downstream Regulatory Element Antagonist Modulator (DREAM).  |  Zhang, J., et al. 2017. Biochemistry. 56: 3523-3530. PMID: 28627884
9. Pb2+ Binds to Downstream Regulatory Element Antagonist Modulator (DREAM) and Modulates Its Interactions with Binding Partners: A Link between Neuronal Calcium Sensors and Pb2+ Neurotoxicity.  |  Azam, S. and Miksovska, J. 2019. ACS Chem Neurosci. 10: 1263-1272. PMID: 30399317
10. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation.  |  Weisskopf, MG., et al. 1993. Nature. 365: 188. PMID: 8103916
11. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain.  |  Hurd, YL. 1996. Neuroscience. 72: 767-83. PMID: 9157322
12. Protein kinase A-dependent derepression of the human prodynorphin gene via differential binding to an intragenic silencer element.  |  Carrión, AM., et al. 1998. Mol Cell Biol. 18: 6921-9. PMID: 9819380

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DREAM Antibody (A-9) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-DREAM Antibody (A-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DREAM Antibody (A-9) Specifications

Alternate Product Name: DREAM

Product Clone Name: A-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 1-214

Epitope Target: DREAM

Epitope Species: human

Product Reactivity/Detection: DREAM

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for DREAM Antibody (A-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin